These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 10589950

  • 1. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.
    Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J.
    Transplantation; 1999 Nov 27; 68(10):1526-32. PubMed ID: 10589950
    [Abstract] [Full Text] [Related]

  • 2. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP, Sirolimus Renal Function Study Group.
    Transplantation; 2002 Dec 15; 74(11):1560-7. PubMed ID: 12490789
    [Abstract] [Full Text] [Related]

  • 3. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.
    MacDonald AS, RAPAMUNE Global Study Group.
    Transplantation; 2001 Jan 27; 71(2):271-80. PubMed ID: 11213073
    [Abstract] [Full Text] [Related]

  • 4. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 5. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure.
    Johnson RW, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J.
    Transplantation; 2001 Sep 15; 72(5):777-86. PubMed ID: 11571437
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Individualization of immunosuppressive therapy: I. Sirolimus improves outcomes in African-American renal transplant recipients.
    Podder H, Kahan BD.
    Transplant Proc; 2005 Nov 15; 37(9):3723-6. PubMed ID: 16386518
    [Abstract] [Full Text] [Related]

  • 10. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
    Morales JM, Campistol JM, Kreis H, Mourad G, Eris J, Schena FP, Grinyo JM, Nanni G, Andres A, Castaing N, Brault Y, Burke JT.
    Transplant Proc; 2005 Mar 15; 37(2):693-6. PubMed ID: 15848504
    [Abstract] [Full Text] [Related]

  • 11. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.
    Russ G, Segoloni G, Oberbauer R, Legendre C, Mota A, Eris J, Grinyó JM, Friend P, Lawen J, Hartmann A, Schena FP, Lelong M, Burke JT, Neylan JF, Rapamune Maintenance Regimen Study Group.
    Transplantation; 2005 Nov 15; 80(9):1204-11. PubMed ID: 16314787
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
    Romagnoli J, Citterio F, Nanni G, Favi E, Tondolo V, Spagnoletti G, Salerno MP, Castagneto M.
    Transplant Proc; 2006 May 15; 38(4):1034-6. PubMed ID: 16757255
    [Abstract] [Full Text] [Related]

  • 14. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.
    Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT.
    Transplantation; 1998 Oct 27; 66(8):1040-6. PubMed ID: 9808489
    [Abstract] [Full Text] [Related]

  • 15. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
    Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattström C, Lebranchu Y, Vialtel P.
    Transplantation; 2000 Apr 15; 69(7):1252-60. PubMed ID: 10798738
    [Abstract] [Full Text] [Related]

  • 16. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
    Morales JM, Hartmann A, Walker R, Arns W, Senatorski G, Grinyó JM, Shoker A, Wilczek H, Jamieson NV, Lelong M, Brault Y, Burke JT, Scarola JA, Rapamune Maintenance Regimen Study Group.
    Transplant Proc; 2009 Apr 15; 41(6):2339-44. PubMed ID: 19715914
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group.
    Neylan JF.
    Transplantation; 1998 Feb 27; 65(4):515-23. PubMed ID: 9500626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.